Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 92752

39 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
July 17, 2023
Product types
Drug
Classifications
Class II
Statuses
Terminated
Recalling firm wording
Central Admixture Pharmacy Services Inc

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

39 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 39

fentaNYL in dextrose 5%, 300 mcg/30 mL, (10 mcg/mL), 30 mL syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C San Diego, CA 92126, NDC: 71286-2001-2

D-1042-2023
Recall number
D-1042-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1,197 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-271144, Exp. 7/25/2023; 17-271354, Exp. 7/27/2023; 17-271681, Exp. 8/2/2023; 17-271990, Exp. 8/7/2023; 17-272457, Exp. 8/16/2023.

Distribution pattern

Nationwide in the USA

drug · product 2 of 39

fentaNYL, 1250 mcg/25 mL, (50 mcg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-7

D-1043-2023
Recall number
D-1043-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
5,124 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270664, Exp. 7/18/2023; 17-270886, Exp. 7/20/2023; 17-270976, 17-270989, Exp. 7/23/2023; 17-271335, Exp. 7/27/2023; 17-271572, Exp. 8/1/2023; 17-271747, Exp. 8/3/2023; 17-271808, Exp. 8/6/2023; 17-272023, Exp. 8/9/2023; 17-272203, Exp. 8/13/2023; 17-272718, Exp. 8/21/2023; 17-272797, Exp. 8/22/2023; 17-273157, Exp. 8/29/2023; 17-273507, Exp. 9/4/2023; 17-273766, Exp. 9/7/2023; 17-273862, Exp. 9/10/2023; 17-274052, Exp. 9/12/2023; 17-274208, Exp. 9/14/2023.

Distribution pattern

Nationwide in the USA

drug · product 3 of 39

HYDROmorphone in 0.9% sodium chloride, 6 mg/30 mL, (0.2 mg/mL), 30 mL Syringe, Rx only, CAPS, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2010-1

D-1044-2023
Recall number
D-1044-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
2,717 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270603, Exp. 7/17/2023; 17-270802, Exp. 7/19/2023; 17-271073, Exp. 7/24/2023; 17-271129, Exp. 7/25/2023; 17-271254, Exp. 7/26/2023; 17-271953, Exp. 8/8/2023; 17-272022, Exp. 8/9/2023; 17-272295, Exp. 8/14/2023; 17-272616, Exp. 8/20/2023; 17-273357, Exp. 8/31/2023; 17-273501, Exp. 9/4/2023.

Distribution pattern

Nationwide in the USA

drug · product 4 of 39

fentaNYL, 100 mcg/2 mL, (50 mcg/mL), 3 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-1

D-1045-2023
Recall number
D-1045-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
150 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-272549, Exp. 8/15/2023; 17-273342, Exp. 8/31/2023; 17-274076, Exp. 9/13/2023.

Distribution pattern

Nationwide in the USA

drug · product 5 of 39

fentaNYL, 250 mcg/5 mL, (50 mcg/mL), 5 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-2

D-1046-2023
Recall number
D-1046-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
100 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-273267, Exp. 8/31/2023.

Distribution pattern

Nationwide in the USA

drug · product 6 of 39

fentaNYL, 2500 mcg/50 mL, (50 mcg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-3

D-1047-2023
Recall number
D-1047-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1,216 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270771, Exp. 7/19/2023; 17-271134, Exp. 7/25/2023; 17-271577, Exp. 8/1/2023; 17-271745, Exp. 8/3/2023; 17-272026, Exp. 8/9/2023; 17-272345, Exp. 8/15/2023; 17-272615, Exp. 8/20/2023; 17-273668, Exp. 9/6/2023.

Distribution pattern

Nationwide in the USA

drug · product 7 of 39

vecuronium, 10 mg/10mL, (1 mg/mL), 10 mL syringe, Rx only, PARALYZING AGENT, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6012-1.

D-1048-2023
Recall number
D-1048-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
2,640 Syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-273867, Exp.9/10/2023; 17-272606, Exp.8/20/2023; 17-272225, 8/13/2023; 17-272036, Exp. 8/9/2023; 17-271503, Exp. 7/31/2023; 17-271427, Exp. 7/30/2023; 17-271264, Exp. 7/26/2023; 17-270970, Exp.7/23/2023; 17-270784, Exp. 7/19/2023; 17-270674, Exp. 7/18/2023.

Distribution pattern

Nationwide in the USA

drug · product 8 of 39

HYDROmorphone in dextrose 5%, 3 mg/30 mL, (0.1 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2013-2

D-1049-2023
Recall number
D-1049-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
2,228 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270675, 17-270683, Exp. 7/18/2023; 17-271147, 17-271119, Exp. 7/25/2023; 17-271339, Exp. 7/27/2023; 17-271679, Exp. 8/2/2023; 17-272202, Exp. 8/10/2023; 17-272241, Exp. 8/13/2023; 17-272375, Exp. 8/15/2023; 17-272783, Exp. 8/22/2023; 17-273438, 17-273431, Exp. 9/3/2023; 17-273615, Exp. 9/5/2023; 17-273789, 9/7/2023.

Distribution pattern

Nationwide in the USA

drug · product 9 of 39

fentaNYL, 2500 mcg/50 mL, (50 mcg/mL), 100 mL bag, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-4

D-1050-2023
Recall number
D-1050-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
848 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270533, Exp. 7/16/2023; 17-270580, 17-270581, Exp. 7/17/2023; 17-270654, Exp. 7/18/2023; 17-271044, Exp. 7/24/2023; 17-271243, Exp. 7/26/2023; 17-271439, Exp. 7/30/2023; 17-271562, Exp. 8/1/2023.

Distribution pattern

Nationwide in the USA

drug · product 10 of 39

fentaNYL, 5000 mcg/100 mL, (50 mcg/mL), 100 mL Bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-5

D-1051-2023
Recall number
D-1051-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
94 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-273074, Exp. 8/28/2023; 17-273772, Exp. 9/7/2023.

Distribution pattern

Nationwide in the USA

drug · product 11 of 39

HYDROmorphone added to 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 100 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2010-3

D-1052-2023
Recall number
D-1052-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
3824 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270599, 17-270600, Exp. 7/17/2023; 17-270785, Exp. 7/19/2023; 17-270969, Exp. 7/23/2023; 17-271116, 17-271135, Exp. 7/25/2023; 17-271242, Exp. 7/26/2023; 17-271502, Exp. 7/31/2023; 17-271561, 17-271589, Exp. 8/1/2023; 17-271672, Exp. 8/2/2023; 17-271837, Exp. 8/6/2023; 17-272291, Exp. 8/14/2023; 17-272363, 17-272364, Exp. 8/15/2023; 17-272453, Exp. 8/16/2023; 17-272607, Exp. 8/20/2023; 17-272706, Exp. 8/21/2023; 17-273148, Exp. 8/29/2023; 17-273421, Exp. 9/3/2023; 17-273698, 17-273700, Exp. 9/6/2023; 17-273966, Exp. 9/11/2023.

Distribution pattern

Nationwide in the USA

drug · product 12 of 39

fentaNYL in 0.9% sodium chloride, 100 mcg/10 mL, (10 mcg/mL), 10 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2071-2

D-1053-2023
Recall number
D-1053-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1669 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270685, Exp. 7/18/2023; 17-271343, Exp. 7/27/2023; 17-271490, Exp. 7/31/2023; 17-271578, Exp. 8/1/2023; 17-272293, Exp. 8/14/2023; 17-272786, Exp. 8/22/2023; 17-273575, Exp. 9/5/2023.

Distribution pattern

Nationwide in the USA

drug · product 13 of 39

fentaNYL in 0.9% sodium chloride, 500 mcg/50 mL, (10 mcg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-3

D-1054-2023
Recall number
D-1054-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
2,082 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-271133, 17-271155, Exp. 7/25/2023; 17-271568, 17-271569, Exp. 8/1/2023; 17-271741, 17-271762, Exp. 8/3/2023; 17-272051, Exp. 8/9/2023; 17-272227, Exp. 8/13/2023; 17-272343, Exp. 8/15/2023; 17-272799, Exp. 8/22/2023; 17-273173, Exp. 8/29/2023; 17-273495, Exp. 9/4/2023.

Distribution pattern

Nationwide in the USA

drug · product 14 of 39

HYDROmorphone in 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2010-2

D-1055-2023
Recall number
D-1055-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
2,389 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270530, Exp. 7/16/2023; 17-270871, Exp. 7/20/2023; 17-271153, Exp. 7/25/2023; 17-271275, Exp. 7/26/2023; 17-271417, Exp. 7/30/2023; 17-271671, Exp. 8/2/2023; 17-271883, Exp. 8/7/2023; 17-271992, Exp. 8/8/2023; 17-272050, Exp. 8/9/2023; 17-272103, Exp. 8/10/2023; 17-272368, 17-272369, Exp. 8/15/2023; 17-272451, Exp. 8/16/2023; 17-273172, Exp. 8/29/2023; 17-273782, Exp. 9/7/2023.

Distribution pattern

Nationwide in the USA

drug · product 15 of 39

succinylcholine, 200 mg/10 mL, (20 mg/mL), 10 mL syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6011-2

D-1056-2023
Recall number
D-1056-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
12,239 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270532, 17-270538, Exp, 7/16/2023; 17-270601, Exp, 7/17/2023; 17-270888, Exp, 7/20/2023; 17-271680, Exp, 8/2/2023; 17-271828, Exp, 8/6/2023; 17-271959, Exp, 8/8/2023; 17-272232, 17-272239, Exp, 8/13/2023; 17-272338, Exp, 8/15/2023; 17-272452, 17-272463, Exp, 8/16/2023; 17-272551, 17-272557, Exp, 8/17/2023; 17-272800, 17-272819, Exp, 8/22/2023; 17-272889, 17-272917, Exp, 8/23/2023; 17-272978, Exp, 8/24/2023; 17-273077, Exp, 8/28/2023; 17-273166, Exp, 8/29/2023; 17-273604, Exp, 9/5/2023; 17-273729, 17-273731, Exp, 9/6/2023; 17-273854, 17-273870, Exp, 9/10/2023;

Distribution pattern

Nationwide in the USA

drug · product 16 of 39

HYDROmorphone in Dextrose 5%, 0.5 mg/5 mL (0.1 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2013-1

D-1057-2023
Recall number
D-1057-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1,389 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270683, Exp 7/18/2023; 17-271119, Exp 7/25/2023; 17-271339, Exp 7/27/2023; 17-272202, Exp 8/10/2023; 17-272241, Exp 8/13/2023; 17-272783, Exp 8/22/2023; 17-273431, Exp 9/3/2023; 17-273615, Exp 9/5/2023

Distribution pattern

Nationwide in the USA

drug · product 17 of 39

HYDROmorphone in 0.9% sodium chloride, 15 mg/30 mL, (0.5 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2011-1

D-1058-2023
Recall number
D-1058-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
2,077 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270770, Exp. 7/19/2023; 17-271061, Exp. 7/24/2023; 17-271419, Exp. 7/30/2023; 17-271678, Exp. 8/2/2023; 17-272124, Exp. 8/10/2023; 17-272302, Exp. 8/14/2023; 17-272518, Exp. 8/17/2023; 17-273493, Exp. 9/4/2023; 17-273671, Exp. 9/6/2023.

Distribution pattern

Nationwide in the USA

drug · product 18 of 39

fentaNYL in 0.9% sodium chloride, 1000 mcg/100 mL, (10 mcg/mL), 100 mL bag, Rx only, CAPS, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-4

D-1059-2023
Recall number
D-1059-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
19,014 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270499, 17-270500, 17-270503, 17-270511, 17-270518, 17-270544, Exp. 7/16/2023; 17-270778, 17-270779, Exp. 7/19/2023; 17-270957, 17-270958, 17-270959, 17-270965, 17-270972, 17-270982, 17-270984, 17-270985, Exp. 7/23/2023; 17-271043, Exp. 7/24/2023; 17-271232, 17-271240, 17-271266, Exp. 7/26/2023; 17-271326, 17-271327, 17-271328, 17-271329, 17-271341, 17-271342, Exp. 7/27/2023; 17-271399, 17-271400, 17-271401, Exp. 7/30/2023; 17-271481, 17-271482, 17-271483, 17-271488, 17-271489, 17-271491, 17-271510, Exp. 7/31/2023; 17-271590, 17-271661, Exp. 8/1/2023; 17-271655, 17-271656, 17-271668, 17-271675, 17-271677, Exp. 8/2/2023; 17-271759, Exp. 8/3/2023; 17-271825, Exp. 8/6/2023; 17-271880, 17-271881, 17-271885, Exp. 8/7/2023; 17-271939, 17-271941, 17-271942, 17-271952, 17-271961, Exp. 8/8/2023; 17-272017, 17-272018, 17-272066, Exp. 8/9/2023; 17-272107, Exp. 8/10/2023; 17-272211, Exp. 8/13/2023; 17-272354, 17-272356, 17-272365, 17-272376, 17-272380, Exp. 8/15/2023; 17-272448, 17-272450, 17-272455, 17-272467, 17-272468, Exp. 8/16/2023; 17-272532, 17-272537, 17-272548, 17-272550, Exp. 8/17/2023; 17-272597, 17-272598, 17-272602, 17-272624, 17-272644, 17-272652, Exp. 8/20/2023; 17-273020, Exp. 8/27/2023; 17-273062, 17-273066, 17-273067, Exp. 8/28/2023; 17-273234, 17-273239, 17-273240, 17-273241, 17-273243, 17-273244, Exp. 8/30/2023; 17-273410, 17-273419, 17-273420, 17-273422, 17-273435, 17-273439, Exp. 9/3/2023; 17-273609, Exp. 9/5/2023; 17-273673, 17-273701, 17-273727, Exp. 9/6/2023; 17-273860, 17-273863, 17-273864, 17-273868, Exp. 9/10/2023; 17-273976, Exp. 9/11/2023; 17-274051, Exp. 9/12/2023.

Distribution pattern

Nationwide in the USA

drug · product 19 of 39

HYDROmorphone in 0.9% sodium chloride, 30 mg/30 mL, (1 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2012-1

D-1060-2023
Recall number
D-1060-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
5,259 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270534, Exp. 7/16/2023; 17-270705, Exp. 7/18/2023; 17-270782, 17-270797, 17-270798, Exp. 7/19/2023; 17-270968, Exp. 7/23/2023; 17-271105, 17-271154, Exp. 7/25/2023; 17-271251, Exp. 7/26/2023; 17-271330, Exp. 7/27/2023; 17-271418, Exp. 7/30/2023; 17-271746, 17-271758, Exp. 8/3/2023; 17-272108, Exp. 8/10/2023; 17-272257, Exp. 8/13/2023; 17-272344, 17-272355, Exp. 8/15/2023; 17-272442, Exp. 8/16/2023; 17-272801, Exp. 8/22/2023; 17-273511, Exp. 9/4/2023; 17-273576, 17-273611, Exp. 9/5/2023; 17-274048, 17-274050, Exp. 9/12/2023.

Distribution pattern

Nationwide in the USA

drug · product 20 of 39

fentaNYL in 0.9% sodium chloride, 2500 mcg/250 mL, (10 mcg/mL), 250 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-5

D-1061-2023
Recall number
D-1061-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
8,146 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270584, 17-270586, 17-270597, 17-270613, Exp. 7/17/2023; 17-270655, 17-270659, 17-270741, Exp. 7/18/2023; 17-270872, 17-270875, Exp. 7/20/2023; 17-271040, 17-271041, 17-271042, 17-271058, 17-271066, 17-271071, 17-271080, Exp. 7/24/2023; 17-271111, 17-271148, 17-271150, 17-271151, 17-271152, 17-271166, Exp. 7/25/2023; 17-271241, 17-271267, Exp. 7/26/2023; 17-271402, 17-271407, 17-271413, 17-271429, Exp. 7/30/2023; 17-271555, 17-271556, 17-271560, 17-271594, Exp. 8/1/2023; 17-271754, Exp. 8/3/2023; 17-271797, 17-271799, 17-271821, 17-271842, Exp. 8/6/2023; 17-271888, 17-271889, Exp. 8/7/2023; 17-271949, 17-271950, Exp. 8/8/2023; 17-272021, 17-272041, Exp. 8/9/2023; 17-272285, 17-272292, 17-272309, 17-272316, Exp. 8/14/2023; 17-272705, 17-272708, 17-272709, 17-272722, 17-272725, Exp. 8/21/2023; 17-272784, 17-272810, Exp. 8/22/2023; 17-272916, Exp. 8/23/2023; 17-272981, 17-272982, 17-272983, 17-272984, Exp. 8/24/2023; 17-273144, 17-273145, 17-273158, 17-273159, 17-273165, Exp. 8/29/2023; 17-273480, 17-273485, 17-273492, 17-273494, 17-273498, Exp. 9/4/2023; 17-273567, 17-273568, 17-273578, 17-273603, Exp. 9/5/2023; 17-273767, 17-273777, 17-273781, Exp. 9/7/2023; 17-273980, Exp. 9/11/2023; 17-274130, 17-274135, Exp. 9/13/2023.

Distribution pattern

Nationwide in the USA

drug · product 21 of 39

fentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2071-7

D-1062-2023
Recall number
D-1062-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
2,340 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270813, Exp. 7/19/2023; 17-271485, Exp. 7/31/2023; 17-271809, Exp. 8/6/2023; 17-272314, Exp. 8/14/2023; 17-272780, Exp. 8/22/2023; 17-273141, Exp. 8/29/2023; 17-273687, Exp. 9/6/2023.

Distribution pattern

Nationwide in the USA

drug · product 22 of 39

fentaNYL in 0.9% sodium chloride, 5000 mcg/250 mL, (20 mcg/mL), 250 mL Bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2074-1

D-1063-2023
Recall number
D-1063-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1,044 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-271115, Exp. 7/25/2023; 17-271398, Exp. 7/30/2023; 17-272278, Exp. 8/14/2023; 17-272449, Exp. 8/16/2023; 17-272521, Exp. 8/17/2023; 17-272900, Exp. 8/23/2023; 17-273146, Exp. 8/29/2023; 17-273236, Exp. 8/30/2023; 17-273404, Exp. 9/3/2023; 17-273678, Exp. 9/6/2023; 17-273954, Exp. 9/11/2023; 17-274213, Exp. 9/14/2023.

Distribution pattern

Nationwide in the USA

drug · product 23 of 39

morphine in 0.9% sodium chloride, 1 mg/1 mL, (1 mg/mL), 3 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2040-1

D-1064-2023
Recall number
D-1064-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1,699 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270804, Exp. 7/19/2023; 17-271108, Exp. 7/25/2023; 17-271496, Exp. 7/31/2023; 17-271844, Exp. 8/6/2023; 17-272045, Exp. 8/9/2023; 17-272288, Exp. 8/14/2023.

Distribution pattern

Nationwide in the USA

drug · product 24 of 39

morphine in 0.9% sodium chloride, 30 mg/30 mL, (1 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2040-3

D-1065-2023
Recall number
D-1065-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
720 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270814, Exp. 7/19/2023; 17-271253, Exp. 7/26/2023; 17-271336, Exp. 7/27/2023; 17-271689, Exp. 8/2/2023.

Distribution pattern

Nationwide in the USA

drug · product 25 of 39

PHENYLephrine in 0.9% sodium chloride, 1000 mcg/10 mL, (100 mcg/mL), 10 mL syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6009-1

D-1066-2023
Recall number
D-1066-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
81,073 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270449, 17-270450, 17-270453, 17-270462, 17-270465, 17-270466, 17-270494, 17-270495, 17-270502, 17-270541, Exp. 7/16/2023; 17-270582, 17-270585, 17-270587, 17-270592, 17-270593, 17-270598, 17-270610, 17-270611, 17-270612, Exp. 7/17/2023; 17-270900, 17-270902, 17-270906, 17-270907, 17-270908, 17-270909, 17-270953, 17-270955, 17-270991, 17-270993, Exp. 7/23/2023; 17-271047, 17-271048, 17-271050, 17-271053, Exp. 7/24/2023; 17-271344, 17-271349, 17-271355, 17-271356, 17-271405, 17-271406, Exp. 7/31/2023; 17-271478, 17-271479, 17-271480, 17-271484, 17-271495, 17-271500, Exp. 7/31/2023; 17-271744, 17-271763, Exp. 8/3/2023; 17-271838, 17-271851, Exp. 8/6/2023; 17-271871, 17-271873, 17-271886, 17-271887, 17-271892, 17-271899, 17-271900, 17-271901, 17-271902, Exp. 8/7/2023; 17-272067, 17-272068, 17-272069, 17-272095, Exp. 8/9/2023; 17-272102, 17-272141, 17-272142, Exp. 8/10/2023; 17-272205, 17-272235, 17-272237, 17-272240, 17-272242, Exp. 8/13/2023; 17-272307, 17-272308, Exp. 8/14/2023; 17-272391, 17-272392, 17-272395, Exp. 8/15/2023; 17-272472, Exp. 8/16/2023; 17-272538, Exp. 8/17/2023; 17-272558, 17-272560, 17-272564, 17-272593, 17-272594, 17-272618, 17-272619, 17-272651, 17-272653, 17-272680, Exp. 8/20/2023; 17-272697, 17-272727, 17-272729, Exp. 8/21/2023; 17-272775, 17-272791, 17-272820, 17-272821, Exp. 8/22/2023; 17-272904, 17-272918, 17-272919, 17-272920, 17-272921, 17-272929, Exp. 8/23/2023; 17-272930, 17-272974, 17-272993, 17-272994, 17-272995, 17-272996, Exp. 8/24/2023; 17-272999, 17-273003, 17-273004, 17-273005, 17-273006, 17-273007, Exp. 8/27/2023; 17-273080, Exp. 8/28/2023; 17-273151, 17-273175, 17-273176, 17-273185, Exp. 8/29/2023; 17-273252, 17-273265, 17-273266, Exp. 8/30/2023; 17-273345, 17-273351, 17-273352, 17-273355, 17-273356, 17-273358, 17-273359, 17-273360, Exp. 8/31/2023; 17-273402, 17-273408, 17-273416, 17-273440, 17-273441, 17-273447, Exp. 9/3/2023; 17-273487, 17-273488, 17-273489, 17-273490, 17-273491, 17-273499, 17-273510, 17-273516, Exp. 9/4/2023; 17-273587, 17-273589, 17-273596, 17-273597, 17-273610, 17-273614, 17-273666, Exp. 9/5/2023; 17-273617, 17-273665, 17-273703, 17-273704, 17-273713, 17-273714, 17-273720, 17-273721, 17-273730, 17-273737, 17-273739, Exp. 9/6/2023; 17-273773, Exp. 9/7/2023; 17-273802, 17-273803, 17-273808, 17-273809, 17-273815, 17-273848, 17-273869, 17-273874, 17-273880, 17-273881, 17-273893, Exp. 9/10/2023; 17-273903, 17-273958, 17-273960, 17-273961, 17-273964, 17-273965, Exp. 9/11/2023.

Distribution pattern

Nationwide in the USA

drug · product 26 of 39

fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 50 mL, Total fentaNYL 75 mcg/50 mL, 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2080-2

D-1067-2023
Recall number
D-1067-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1,486 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270811, Exp. 7/19/2023; 17-270954, 17-270983, Exp. 7/23/2023; 17-271231, Exp. 7/26/2023; 17-271690, Exp. 8/2/2023; 17-272204, Exp. 8/13/2023; 17-272684, Exp. 8/20/2023; 17-272992, Exp. 8/24/2023; 17-273053, Exp. 8/28/2023; 17-273436, Exp. 9/3/2023.

Distribution pattern

Nationwide in the USA

drug · product 27 of 39

morphine in 0.9% sodium chloride, 125 mg/25 mL, (5 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2041-2

D-1068-2023
Recall number
D-1068-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
723 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-271060, Exp. 7/24/2023; 17-271252, Exp. 7/26/2023; 17-271571, Exp. 8/1/2023; 17-272471, Exp. 8/16/2023; 17-272785, Exp. 8/22/2023.

Distribution pattern

Nationwide in the USA

drug · product 28 of 39

fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volume = 250 mL, Total fentaNYL 500 mcg/250 mL, 250 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2081-1

D-1069-2023
Recall number
D-1069-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
295 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-271814, Exp. 8/6/2023; 17-271960, Exp. 8/8/2023; 17-272252, Exp. 8/13/2023; 17-272272, Exp. 8/14/2023; 17-272454, Exp. 8/16/2023; 17-272640, Exp. 8/20/2023; 17-272716, Exp. 8/21/2023.

Distribution pattern

Nationwide in the USA

drug · product 29 of 39

fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride, Total Volume = 100 mL, Total FentaNYL 200 mcg/100 mL, 100 mL bag, Rx only, CAPS, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2082-1

D-1070-2023
Recall number
D-1070-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1,114 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-274485, Exp. 9/19/2023; 17-270783, Exp. 7/19/2023; 17-270882, Exp. 7/20/2023; 17-271430, Exp. 7/30/2023; 17-271509, Exp. 7/31/2023; 17-272224, 17-272238, Exp. 8/13/2023; 17-272704, Exp. 8/21/2023; 17-273147, Exp. 8/29/2023.

Distribution pattern

Nationwide in the USA

drug · product 30 of 39

ketamine in 0.9% sodium chloride, 50 mg/5mL (10mg/mL), 5 mL syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-3022-1

D-1071-2023
Recall number
D-1071-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
2,994 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-274122, 17-274147, 17-274155, 17-274158, 17-274162, Exp. 9/13/2023

Distribution pattern

Nationwide in the USA

drug · product 31 of 39

fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride / Total Volume = 250 mL, Total fentaNYL 500 mcg/250 mL, bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2082-2

D-1072-2023
Recall number
D-1072-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
896 bags

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270540, Exp. 7/16/2023; 17-270663, Exp. 7/18/2023; 17-271059, Exp. 7/24/2023; 17-271249, Exp. 7/26/2023; 17-271593, Exp. 8/1/2023; 17-271742, Exp. 8/3/2023; 17-272064, Exp. 8/9/2023; 17-272106, Exp. 8/10/2023; 17-272279, Exp. 8/14/2023; 17-272530, Exp. 8/17/2023; 17-272603, Exp. 8/20/2023; 17-272776, Exp. 8/22/2023; 17-273075, Exp. 8/28/2023; 17-273344, Exp. 8/31/2023; 17-273409, Exp. 9/3/2023; 17-274221, 17-274222, Exp. 9/14/2023; 17-274414, Exp. 9/18/2023.

Distribution pattern

Nationwide in the USA

drug · product 32 of 39

ePHEDrine in 0.9% sodium chloride, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, CAPS Inc., Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6004-1

D-1073-2023
Recall number
D-1073-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
8,942 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270545, Exp. 7/16/2023; 17-270614, Exp. 7/17/2023; 17-270885, 17-270897, Exp. 7/20/2023; 17-270980, 17-270992, Exp. 7/23/2023; 17-271268, Exp. 7/26/2023; 17-271338, Exp. 7/27/2023; 17-271426, 17-271428, Exp. 7/30/2023; 17-271691, Exp. 8/2/2023; 17-271843, Exp. 8/6/2023; 17-271963, Exp. 8/8/2023; 17-272136, Exp. 8/10/2023; 17-272215, Exp. 8/13/2023; 17-272304, Exp. 8/14/2023; 17-272379, Exp. 8/15/2023; 17-272462, Exp. 8/16/2023; 17-272641, Exp. 8/20/2023; 17-272698, Exp. 8/21/2023; 17-273602, 17-273627, Exp. 9/5/2023; 17-273883, Exp. 9/10/2023.

Distribution pattern

Nationwide in the USA

drug · product 33 of 39

lidocaine 2%, 100 mg /5 mL, (20 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6006-1

D-1074-2023
Recall number
D-1074-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
9,517 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-271076, Exp. 7/24/2023; 17-271132, 17-271165, Exp. 7/25/2023; 17-271230, 17-271250, Exp. 7/26/2023; 17-271508, Exp. 7/31/2023; 17-271595, 17-271604, Exp. 8/1/2023; 17-271658, Exp. 8/2/2023; 17-271764, Exp. 8/3/2023; 17-271826, Exp. 8/6/2023; 17-271972, Exp. 8/8/2023; 17-272052, 17-272057, Exp. 8/9/2023; 17-272139, Exp. 8/10/2023; 17-272258, Exp. 8/14/2023; 17-272470, Exp. 8/16/2023; 17-272690, Exp. 8/20/2023; 17-272822, Exp. 8/23/2023; 17-273054, 17-273065, Exp. 8/28/2023; 17-273423, Exp. 9/2/2023; 17-273771, Exp. 9/7/2023.

Distribution pattern

Nationwide in the USA

drug · product 34 of 39

midazolam in dextrose 5%, 50 mg /50 mL, (1 mg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-4036-1

D-1075-2023
Recall number
D-1075-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
621 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270666, Exp. 7/18/2023; 17-270879, Exp. 7/20/2023; 17-271669, Exp. 8/2/2023; 17-272287, Exp. 8/14/2023; 17-272366, Exp. 8/15/2023; 17-272991, Exp. 8/24/2023; 17-273512, Exp. 9/4/2023.

Distribution pattern

Nationwide in the USA

drug · product 35 of 39

rocuronium, 50 mg /5 mL, (10 mg/mL), 5 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6010-1

D-1076-2023
Recall number
D-1076-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
10,065 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270519, Exp. 7/16/2023; 17-270605, Exp. 7/17/2023; 17-270684, Exp. 7/18/2023; 17-270898, Exp. 7/20/2023; 17-271074, Exp. 7/24/2023; 17-271324, Exp. 7/27/2023; 17-271603, Exp. 8/1/2023; 17-271670, Exp. 8/2/2023; 17-272529, Exp. 8/17/2023; 17-272883, Exp. 8/23/2023; 17-273235, 17-273245, 17-273262, 17-273263, 17-273264, Exp. 8/30/2023; 17-273418, Exp. 9/3/2023; 17-273768, 17-273788, Exp. 9/7/2023; 17-274022, Exp. 9/12/2023.

Distribution pattern

Nationwide in the USA

drug · product 36 of 39

PHENYLephrine in 0.9 sodium chloride, 800 mcg /10 mL, (80 mcg/mL), 10 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6008-1

D-1077-2023
Recall number
D-1077-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
10,494 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270678, 17-270695, Exp. 7/18/2023; 17-270880, Exp. 7/20/2023; 17-271075, Exp. 7/24/2023; 17-271233, 17-271269, Exp. 7/26/2023; 17-271492, 17-271494, Exp. 7/31/2023; 17-271748, Exp. 8/3/2023; 17-271891, Exp. 8/7/2023; 17-271945, Exp. 8/8/2023; 17-272221, 17-272236, Exp. 8/13/2023; 17-272286, 17-272305, Exp. 8/14/2023; 17-272642, Exp. 8/20/2023; 17-272997, 17-272998, Exp. 8/24/2023; 17-273478, 17-273496, 17-273497, Exp. 9/4/2023; 17-274139, 17-274156, 17-274163, Exp. 9/13/2023.

Distribution pattern

Nationwide in the USA

drug · product 37 of 39

PHENYLephrine in 0.9 sodium chloride, 400 mcg /10 mL, (40 mcg/mL), 10 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6007-1

D-1078-2023
Recall number
D-1078-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
16,971 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270510, 17-270512, Exp. 7/16/2023; 17-270665, 17-270699, Exp. 7/18/2023; 17-270812, Exp. 7/19/2023; 17-271062, 17-271063, 17-271064, 17-271065, Exp. 7/24/2023; 17-271350, 17-271357, 17-271421, 17-271422, Exp. 7/30/2023; 17-271836, 17-271848, Exp. 8/6/2023; 17-271890, Exp. 8/7/2023; 17-271943, 17-271954, 17-271958, 17-271962, Exp. 8/8/2023; 17-272162, 17-272174, 17-272175, 17-272176, 17-272177, Exp. 8/13/2023; 17-272444, 17-272456, 17-272473, Exp. 8/16/2023; 17-272717, 17-272721, 17-272732, Exp. 8/21/2023; 17-273550, 17-273565, 17-273579, 17-273580, Exp. 9/5/2023.

Distribution pattern

Nationwide in the USA

drug · product 38 of 39

fentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C San Diego, CA 92126, NDC: 71286-2071-1

D-1079-2023
Recall number
D-1079-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
6,770 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-270539, Exp. 7/16/2023; 17-270981, Exp. 7/23/2023; 17-271167, Exp. 7/25/2023; 17-271337, Exp. 7/27/2023; 17-271827, Exp. 8/6/2023; 17-272214, Exp. 8/13/2023; 17-272536, 17-272555, Exp. 8/17/2023; 17-273424, 17-273432, Exp. 9/3/2023; 17-273476, Exp. 9/4/2023; 17-273882, Exp. 9/10/2023; 17-274044, Exp. 9/12/2023.

Distribution pattern

Nationwide in the USA

drug · product 39 of 39

morphine in 0.9% Sodium Chloride, 50 mg/50 mL (1mg/mL), 50 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C San Diego, CA 92126, NDC: 71286-2040-4

D-1080-2023
Recall number
D-1080-2023
Initiated
July 17, 2023
Classification
Class II
Status
Terminated
Quantity
1,235 syringes

App-derived interpretation

Sterility assurance reason.sterility_assurance · v1.0.0
Lack of assurance of sterility

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Lack of assurance of sterility: Lack of validation data for sanitization cycles

Code information

Lot: 17-273353, Exp 8/31/2023, 17-270602, Exp 7/17/2023; 17-270706, Exp 7/18/2023; 17-271416, Exp 7/30/2023; 17-272049, Exp 8/9/2023; 17-272277, Exp 8/14/2023; 17-273231, Exp 8/30/2023.

Distribution pattern

Nationwide in the USA